Inhibitors of prostasin

Details Inhibitors of prostasin Inhibitors of prostasin

2003-05-08

2010-02-23

Lukton, David (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

C530S325000, C530S326000, C514S002600, C514S012200, C514S013800, C514S014800

Reexamination Certificate

active

07666981

ABSTRACT:
A class of proteins useful as inhibitors of prostasin and method for identifying them are provided. These proteins have the structure wherein the amino acids P1-P4 from the scissile bond are respectively leu-ile-ala-arg and the amino acids at positions P5-P15 are serpin sequences.

REFERENCES:
patent: 5326562 (1994-07-01), Scott
patent: 5686419 (1997-11-01), Powers et al.
patent: 5871917 (1999-02-01), Duffy
patent: 6043033 (2000-03-01), Bandman et al.
patent: 6048970 (2000-04-01), Lal et al.
patent: 6075136 (2000-06-01), Tang et al.
patent: 6090559 (2000-07-01), Russell et al.
patent: 6090786 (2000-07-01), Augustyns et al.
patent: 6107049 (2000-08-01), Allard et al.
patent: 6303318 (2001-10-01), O'Brien
patent: 6420157 (2002-07-01), Darrow et al.
patent: 2001/0016331 (2001-08-01), Kominami et al.
patent: 000251505 (1988-01-01), None
Chen (Int J Cancer 97(3), 323-329, 2002).
Chen (The Prostate 66(9), 911-20, 2006).
Donaldson (J. Biol. Chem. 277, 8338-8345, 2002).
Aihara M. Lebovitz RM. Wheeler TM. Kinner BM. Ohori M. Scardino PT. Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. Journal of Urology. 151(6):1558-64, 1994.
Akazaki K. Stemmerman GN. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. Journal of the National Cancer Institute. 50(5):1137-44, 1973.
Bastacky SI. Wonjo KJ. Walsh PC. Carmichael MJ. Epstein JI. Pathological features of hereditary prostate cancer. Journal of Urology. 153(3 Pt 2):987-92, 1995.
Berteau P. Laribi A. Eschwege P. Lebars I. Dumars F. Benoit G. Loric S. Prostasin mRNA to detect prostate cells in blood of cancer patients. Clinical and Chemical Laboratory Medicine 37 (SS): S119, 1999.
Bussemakers MJ. van Moorselaar RJ. Giroldi LA. Ichikawa T. Isaacs JT. Takeichi M. Debruyne FM. Schalken JA. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Research. 52(10):2916-22, 1992.
Carter H. Coffey D. Prostate Cancer: the magnitude of the problem in the United States. InA Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. (Eds. Coffey D. Resnick M. Door R. et al.), pp. 1-9, Plenum Press, 1988.
Carter HB. Piantadosi S. Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. Journal of Urology. 143(4):742-6, 1990.
Catalona WJ. Partin AW. Slawin KM. Brawer MK. Flanigan RC. Patel A. Richie JP. deKernion JB. Walsh PC. Scardino PT. Lange PH. Subong EN. Parson RE. Gasior GH. Loveland KG. Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial [see comments]. JAMA. 279(19):1542-7, 1998.
Denis LJ. Staging and prognosis of prostate cancer. European Urology. 24 Suppl 2:13-8, 1993.
Dong JT. Lamb PW. Rinker-Schaeffer CW. Vukanovic J. Ichikawa T. Isaacs JT. Barrett JC. KAI1, a metastasis.
Dong JT. Suzuki H. Pin SS. Bova GS. Schalken JA. Isaacs WB. Barrett JC. Isaacs JT. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Research. 56(19):4387-90, 1996.
Dunn JE. Cancer epidemiology in populations of the United States—with emphasis on Hawaii and California—and Japan. Cancer Research. 35(11 Pt. 2):3240-5, 1975.
Emmert-Buck, et al., Laser Capture MicrodissectionScience, vol. 274, Nov. 8, 1997, pp. 998-1001.
Ernster VL. Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. [Review] [34 refs] Journal of the National Cancer Institute. Monographs. (22):151-6, 1997 .
Fornaro M. Tallini G. Bofetiado CJ. Bosari S. Languino LR. Down-regulation of beta 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma. American Journal of Pathology. 149(3):765-73, 1996.
Fornaro M. Manzotti M. Tallini G. Slear AE. Bosari S. Ruoslahti E. Languino LR. Beta1C integrin in epithelial cells correlates with a nonproliferative phenotype: forced expression of beta1C inhibits prostate epithelial cell proliferation. American Journal of Pathology, 153(4):1079-87, 1998.
Fornaro M. Tallini G. Zheng DQ. Flanagan WM. Manzotti M. Languino LR. p27(kip1) acts as a downstream effector of and is coexpressed with the beta1C integrin in prostatic adenocarcinoma. Journal of Clinical Investigation 103(3):321-9, 1999.
Gao AC. Lou W. Dong JT. Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Research. 57(5):846-9, 1997.
Gleason DF. Classification of prostatic carcinomas. Cancer Chemotherapy Reports—Part 1. 50(3):125-8, 1966.
Gleason DF. Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. Journal of Urology. 111(1):58-64, 1974.
Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V. The role for NESI serine protease as a novel tumor suppressor. Cancer Res 58:4782-4786, 1998.
Greene GF. Kitadai Y. Pettaway CA. von Eschenbach AC. Bucana CD. Fidler IJ. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messanger RNA hybridization technique. American Journal of Pathology. 150(5):1571-82, 1997.
Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. Ca: a Cancer Journal for Clinicians 2000;50:7-33.
Haenszel W. Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. Journal of the National Cancer Institute. 49(1):43-68, 1968.
Hakalahti L. Vihko P. Henttu P. Autio-Harmainen H. Sonini Y. Vihko R. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. International Journal of Cancer. 55(4):590-7, 1993.
Hooper JD. Nicol DL. Dickinson JL. Eyre HJ. Scarman AL. Normyle JF. Stuttgen MA. Douglas ML. Loveland KA. Sutherland GR. Antalis TM. Testisin, a new human serine proteinase expressed by premeiotic testicular germ cells and lost in testicular germ cell tumors. Cancer Research. 59(13):3199-205, 1999.
Hwang ES. Esserman LJ. Management of ductal carcinoma in situ. [Review] [91 refs] Surgical Clinics of North America. 79(5):1007-30, viii, 1999.
Isaacs JT. Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. [Review] [92 refs] American Journal of Pathology. 150(5):1511-21, 1997.
Isaacs JT. Bova GS. Prostate Cancer. InThe Genetic Basis of Human Cancer(Eds. Vogelstein B and Kinzler KW), pp. 653-660, McGraw-Hill Health Professions Division, 1998.
Kennedy AR. Chemopreventive agents: protease inhibitors. Pharmacol Therapeut 78:167-209, 1998.
Knuutila S. Aalto Y. Autio K. Bjorkqvist AM. El-Rifai W. Hemmer S. Huhta T. Kettunen E. Kiuru-Kuhlefelt S. Larramendy ML. Lushnikova T. Monni O. Pere H. Tapper J. Tarkkanen M. Varis A. Wasenius VM. Wolf M. Zhu Y. DNA copy number losses in human neoplasms. [Review] [197 refs] American Journal of Pathology. 155(3):683-94, 1999.
Liu DF. Rabbani SA. Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3. Prostate. 27(5):269-76, 1995.
Lou W. Krill D. Dhir R. Becich MJ. Dong JT. Frierson HF Jr. Isaacs JT. Gao AC. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Research. 59(10):2329-31, 1999.
Lou J. Lubaroff DM. Hendrix MJ. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Research. 59(15):3552-6, 1999.
Mignatti P. Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. [Review] [306 refs] Physiological Reviews. 73(1):161-95, 1993.
Mirchandani D. Zheng J. Miller GJ. Ghosh AK. Shibata DK. Cote RJ. Roy-Burman P. Heterogeneity in intratumor distribution of p53 muta

Affiliated with

Also associated with

Rating

Inhibitors of prostasin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of prostasin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of prostasin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4165475